Scientific Letters
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases
Morphologic leukemia-free state after venetoclax-based therapy in acute myeloid leukemia is associated with high relapse despite preserved short-term survival
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: April 30, 2026
0
Views
0
Downloads
0
HTML
Authors
Early morphologic leukemia-free state (MLFS) after venetoclax combination therapy in untreated acute myeloid leukemia (AML) may represent a clinically distinct response state rather than remission-equivalent disease control.
Downloads
Download data is not yet available.
Citations
References
1. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373:1136-52. https://doi.org/10.1056/NEJMra1406184
2. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7-17. https://doi.org/10.1182/blood-2018-08-868752
3. Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137-45. https://doi.org/10.1182/blood.2020004856
4. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-47. https://doi.org/10.1182/blood-2016-08-733196
5. Jonas BA, Wei AH, Recher C, DiNardo CD, Pratz KW, Potluri J, et al. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2022;97:E299-303. https://doi.org/10.1002/ajh.26597
6. Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2021;96:208-17. https://doi.org/10.1002/ajh.26039
7. Shallis RM, Pollyea DA, Zeidan AM. The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses. Blood Rev. 2021;48:100806. https://doi.org/10.1016/j.blre.2021.100806
8. Hassan H, Rompola M, Glaser AW, Kinsey SE, Phillips RS. Validation of a classification system for treatment-related mortality in children with cancer. BMJ Paediatr Open. 2017;1:e000082. https://doi.org/10.1136/bmjpo-2017-000082
9. Pratz KW, Jonas BA, Pullarkat V, Wei AH, Schuh AC, Recher C, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99:615-24. https://doi.org/10.1002/ajh.27218
10. Garciaz S, Hospital MA, Alary AS, Gelsi-Boyer V, Hafi K, D'Incan E, et al. Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients. Cancers (Basel). 2022;14:2025. https://doi.org/10.3390/cancers14082025
11. Jain AG, Volpe VO, Wang C, Abunnaja S, El-Jawahri A, Bewersdorf JP, et al. Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia. Ann Hematol. 2024. https://doi.org/10.1007/s00277-024-05976-6
12. DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791-803. https://doi.org/10.1182/blood.2019003988
13. Yan M, Wang G, Wang J, Xu L. Efficacy of venetoclax combined with azacitidine in elderly patients with relapsed acute myeloid leukemia. Mediterr J Hematol Infect Dis. 2025;17(1):e2025058. https://doi.org/10.4084/MJHID.2025.058
Ethics Approval
AML , VenetoclaxSupporting Agencies
NoneHow to Cite
“Morphologic leukemia-free state after venetoclax-based therapy in acute myeloid leukemia is associated with high relapse despite preserved short-term survival” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026048. doi:10.4084/MJHID.2026.048.
Copyright (c) 2026 Kenta Motegi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
